SCHEMBL6709574

SCHEMBL6709574

CC(C)c1cnc(N(C(N)=O)c2ccc(-c3cn4ccccc4n3)cc2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
CLK1 P49759 1/20 0.44
DYRK1A Q13627 1/20 0.44
RAB9A P51151 11/20 0.43
NPC1 O15118 11/20 0.43
KDM4E B2RXH2 10/20 0.43
GFER P55789 3/20 0.43
ALDH1A1 P00352 8/20 0.43
SMN1; SMN2 Q16637 7/20 0.43
HPGD P15428 4/20 0.43
HDAC6 Q9UBN7 1/20 0.43
PKM P14618 4/20 0.42
MAPK1 P28482 2/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
EPHX2 P34913 1/20 0.42
GAA P10253 1/20 0.42
MIF P14174 1/20 0.42
POLB P06746 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711707 0.78 MLYCD (0.47) PTGS2RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL6711875 0.76 KDM4E (0.42) KDM4EALDH1A1HPGDGAAHTT
SCHEMBL27572548 0.74 CDK2 (0.38) PTGS2ALDH1A1SMN1; SMN2EPHX2GAA
SCHEMBL27570619 0.74 CDK2 (0.38) ALDH1A1SMN1; SMN2
SCHEMBL7257113 0.74 CDK2 (0.38) PTGS2ALDH1A1SMN1; SMN2EPHX2GAA
SCHEMBL6287749 0.74 CDK2 (0.61) PTGS1PTGS2RAB9ANPC1KDM4E
SCHEMBL27574287 0.73 CCNE1 (0.37) ALDH1A1SMN1; SMN2KMT2AMEN1L3MBTL1
SCHEMBL6710898 0.73 MLYCD (0.38) ALDH1A1SMN1; SMN2EPHX2TSHR
SCHEMBL28748134 0.73 ACACB (0.47) ALDH1A1SMN1; SMN2
SCHEMBL6713166 0.73 NPC1 (0.43) RAB9ANPC1KDM4EGFERALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 PTGS1 2424/4885PTGS2 2563/4885CLK1 655/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 PTGS1 2424/4885PTGS2 2563/4885CLK1 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.